BridgeMD
Comparing a pain pump and standard pain medication for severe cancer pain
EU CTIS ID: 2025-522381-68-00
What this study is testing
Health related quality of life
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (≥18 years) with severe cancer refractory pain (all types of cancer), who have been receiving treatment with opioids for at least 4 weeks, and are expected to remain on opioids for the entire duration of the study. More than one opioid rotation has to be done before defining pain refractoriness.
- Intrathecal therapy is recommended because of inefficacy or intolerance to strong systemic opioid treatment. Inefficacy is defined as mean daily visual analogue scale (VAS) pain inten-sity score at rest of ≥ 50 mm. Intolerance is defined as the occurrence of (severe) adverse events (AE) (even with dosage less than 200 mg/day of oral morphine equivalents) which prevents a further increase in the opioid dosage to obtain pain relief.
- Patients suitable for IDD and with the ability to comply with the medical protocol and visits.
- Survival prognosis of ≥ 3 months.
You likely can't join if
- Patients with active, severe infection.
- Patients with known brain metastases.
- Patients with high risk of hemorrhaging.
- Patients with allergies for medication or IDD hardware.
- Pregnant or lactating women.
- Women who plan to become pregnant within 1 month after the study.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.